All (n=166) | DAS<1.6 (n=72) | DAS28<2.6 (n=56) | DAS28<2.0 (n=22) | SDAI≤3.3 (n=28) | ACR/EULAR (n=23) | |
---|---|---|---|---|---|---|
Age, median (IQR) | 60 (50–72) | 62 (46–74) | 57 (44–68) | 57 (45–67) | 57 (44–63) | 56 (45–67) |
Female, n (%) | 121 (73) | 43 (59) | 35 (63) | 11 (50) | 19 (67) | 14 (61) |
Symptom duration, months, median (IQR) | 16 (15–18) | 16 (15–18) | 16 (15–18) | 16 (15–18) | 15 (14–18) | 16 (15–19) |
RF positive, n (%) | 68 (41) | 28 (39) | 26 (46) | 8 (37) | 13 (46) | 11 (47) |
28 Swollen joints, median (IQR) | 3 (1–5) | 2 (1–3) | 2 (1–2) | 1 (0–2) | 1 (0–1) | 1 (0–1) |
28 Tender joints, median (IQR) | 1 (0–3) | 0 (0–0) | 0 (0–0) | 0 (0–0) | 0 (0–0) | 0 (0–0) |
44 Swollen joints, median (IQR) | 4 (2–7) | 3 (2–4.5) | 2 (1–3) | 2 (0–3) | 1.5 (0–2) | 1 (0–2) |
44 Tender joints, median (IQR) | 2 (0–5) | 0 (0–0) | 0 (0–1) | 0 (0–0) | 0 (0–1) | 0 (0–1) |
VAS PtGA, mm, median (IQR) | 16.5 (2–42) | 5 (0–20) | 3.5 (0–23) | 2.5 (0–16) | 0 (0–2) | 0 (0–2) |
VAS pain, mm, median (IQR) | 20 (3–45) | 8 (1–21) | 7.5 (1–21) | 4 (0–15) | 1.5 (0–5) | 1 (0–5) |
VAS physician, mm, median (IQR) | 15 (7–25) | 10 (5–18) | 8 (5–18) | 5 (0–10) | 4 (0–5) | 3 (0–5) |
VAS GH, mm, median (IQR) | 20 (10–36) | 14 (9–24) | 10 (8–21) | 10 (8–22) | 10 (8–20) | 10 (7–26) |
ESR, mm/h, median (IQR) | 14 (8–23) | 10 (6–21) | 8 (4–13) | 3.5 (2–7) | 8.5 (4–16) | 8 (4–17) |
CRP, mg/dl, median (IQR) | 0.25 (0.1–0.4) | 0.22 (0.12–0.39) | 0.2 (0.1–0.3) | 0.13 (0.1–0.29) | 0.17 (0.1–0.31) | 0.17 (0.1–0.3) |
Methotrexate, n (%) | 120 (72) | 51 (70) | 34 (60) | 7 (33) | 15 (53) | 14 (61) |
Steroid, n (%) | 66 (39) | 31 (43) | 30 (54) | 13 (59) | 13 (46) | 12 (52) |
Outcome measures | ||||||
HAQ score, median (IQR) | 0.125 (0–0.75) | 0 (0–0.25) | 0 (0–0.25) | 0 (0,0.125) | 0 (0–0.18) | 0 (0–0.25) |
HAQ≤0.5, n (%) | 113 (68.5) | 62 (86.1) | 49 (87.5) | 21 (95.4) | 27 (96.4) | 22 (95.6) |
Absent PDPS, n (%) | 107 (64) | 50 (69) | 43 (77) | 19 (86) | 25 (90) | 21 (91) |
Data are presented for the overall population and separately for groups of patients fulfilling different remission criteria.
ACR/EULAR, American College of Rheumatology/European League Against Rheumatism; CRP, C-reactive protein; DAS, disease activity score; DMARD, disease-modifying antirheumatic drug; ESR, erythrolcyte sedimentation rate; GH, global health; HAQ, health assessment questionnaire; PDPS, power Doppler-positive synovitis; PtGA, patient's global assessment; RF, rheumatoid factor; SDAI, simplified disease activity index; VAS, visual analogue scale.